Program
letermovir
Also written as “Letermovir”, “Letermovir tablet” and “Letermovir oral granules”.
Its studies are mostly in Cytomegalovirus Infections, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 71 open or running | phase 3since May 12, 2014 | May 12, 2014 | Apr 14, 2028phase 1 · NCT07199465 |
| AiCuris Anti-infective Cures | 10 open or running | phase 2since Feb 4, 2010 | Feb 4, 2010 | none ahead |
Also a collaborator on its studies: quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2010First study: phase 2 study in HCMV Reactivation or HCMV End-Organ DiseaseNew to AiCuris Anti-infective CuresAiCuris Anti-infective Cures · NCT01063829 · 133 enrolled · United States, Germany
- May 12, 2014Merck's first study: phase 3 study in DiseaseNew to MerckMerck · NCT02137772 · 570 enrolled
- Feb 19, 2018Phase 3 study in CMV DiseaseMerck · NCT03443869 · 601 enrolled · United States, Argentina, Australia and more
- Apr 26, 2019Phase 3 study in Cytomegalovirus InfectionsMerck · NCT03930615 · 220 enrolled · United States, France, Germany and more
- May 6, 2019Phase 2 study in Cytomegalovirus InfectionsMerck · NCT03940586 · 65 enrolled · United States, Australia, Colombia and more
- Oct 15, 2019Phase 3 study in Cytomegalovirus InfectionsMerck · NCT04129398 · 22 enrolled · Japan
- Feb 28, 2023Phase 3 study in Cytomegalovirus InfectionsMerck · NCT05763823 · 120 enrolled · China
- Sep 22, 2025Phase 1 study in Cytomegalovirus ProphylaxisMerck · NCT07199465 · 40 planned · United States
Ahead
- Apr 14, 2028Primary completion: phase 1 study in Cytomegalovirus ProphylaxisMerck · NCT07199465
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA terminase inhibitor”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07199465Cytomegalovirus Prophylaxis · United States | 1 | Recruiting | Merck | Apr 14, 2028 | 40 |
| NCT05763823Cytomegalovirus Infections · China | 3 | Completed | Merck | Apr 18, 2024 | 120 |
| NCT04129398Cytomegalovirus Infections · Japan | 3 | Completed | Merck | Oct 6, 2022 | 22 |
| NCT03940586Cytomegalovirus Infections · United States, Australia, Colombia and more | 2 | Completed | Merck | Jan 4, 2023 | 65 |
| NCT03930615Cytomegalovirus Infections · United States, France, Germany and more | 3 | Completed | Merck | Oct 27, 2021 | 220 |
| NCT03443869CMV Disease · United States, Argentina, Australia and more | 3 | Completed | Merck | Apr 5, 2022 | 601 |
| NCT02137772Disease | 3 | Completed | Merck | Aug 8, 2016 | 570 |
| NCT01063829HCMV Reactivation or HCMV End-Organ Disease · United States, Germany | 2 | Completed | AiCuris Anti-infective Cures | Oct 2011 | 133 |
How it is read
Names in the registry
- “Letermovir”, 5 entries
- “Letermovir tablet”, 2 entries
- “Letermovir oral granules”, 1 entry
- “Letermovir intravenous”, 1 entry
- “Letermovir IV”, 1 entry
Conditions, from the studies’ own filings
- Cytomegalovirus Infections, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.